Abstract:Estrogen receptor positive (ER+) breast cancer has ability to metastasize to bone in high frequency. Bone is known to be fertile soil for metastasized cancer cells to survive and in turn, metastasized tumor cells alter normally balanced bone environment. Prevention and treatment of bone metastasis is challenging and better understanding why bone metastasis are resistant to current therapies is needed. Aim of the present study was to explore the role of tumor microenvironment and estrogen supplementation on growth of primary breast cancer tumor and bone metastasis to establish predictive ER+ breast cancer models for drug development. ER+ human breast cancer MCF-7 cells were inoculated into mammary fat pad and in the tibia of female athymic nude mice. Mice received either hormonal supplementation (17-beta estradiol pellet, E2) or placebo. Tumor growth was followed for 5 and 9 weeks. From one group, E2 supplementation was removed on study week 5 and tumor growth was followed for 4 weeks. During the study, blood samples were collected for serum steroid concentration measurements and at the end, histopathological evaluation and immunohistochemical (IHC) stainings were performed to examine tumor steroid hormone receptor expression. Orthotopic MCF-7 tumor growth was clearly hormone dependent. E2 supplementation, that increased serum estradiol for app. 3-fold, supported tumor growth and when E2 was removed, tumor size decreased and no tumor growth was observed thereafter. In the full absence of E2 supplement, no orthotopic tumor growth was observed. In contrast, when MCF-7 cells were inoculated into tibia, tumor growth was observed both with and without E2 supplement. IHC stainings confirmed orthotopic tumor to express ER, PR and AR when animals received E2. After E2 removal, orthotopic tumors expressed still ER and AR but no longer PR. Also intratibial tumors expressed ER and PR in the presence of E2, but no PR in the absence of E2 supplement. E2 is needed to support MCF-7 tumor growth when cancer cells are inoculated orthotopically into mammary fat pad. No orthotopic tumor growth is observed in the absence of E2 supplement. In contrast, in the bone microenvironment, MCF-7 cells form tumor even in the absence of E2 supplement. Results highlight importance of tumor microenvironment in the breast cancer progression and also refer why tumor in the different sites may be resistant to therapy. Taking together, when developing new therapies against breast cancer, focus should be addressed not only on primary tumor growth but also on bone metastasis where cancer cells are under influence of bone environment. Citation Format: Jenni Bernoulli, Mari I. Suominen, Tiina Kahkonen, Jenni Maki-Jouppila, Jussi M. Halleen, Riikka Oksala. Importance of tumor microenvironment in the preclinical estrogen receptor positive breast cancer- Primary tumor and bone metastasis models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 4968. doi:10.1158/1538-7445.AM2017-4968

Human breast cancer in the athymic nude mouse: Cystostatic effects of long-term antiestrogen therapy

[Experimental chemo- and chemoendocrine therapy of human breast carcinomas serially transplanted into nude mice]

[A Study on the Effect of Tanshinone II A Against Human Breast Cancer in Vivo].

In vivo studies by magnetic resonance imaging and spectroscopy of the response to tamoxifen of MCF7 human breast cancer implanted in nude mice

Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer

Tamoxifen induced changes in MCF7 human breast cancer: in vitro and in vivo studies using nuclear magnetic resonance spectroscopy and imaging

Effects on Xenografts in Nude Mice of Estrogen Receptor Β Expression

Tamoxifen induces hepatotoxicity and changes to hepatocyte morphology at the early stage of endocrinotherapy in mice

Cell therapy of a highly invasive human breast carcinoma implanted in immunodeficient (SCID) mice

Estrogen receptor alpha in the brain mediates tamoxifen-induced changes in physiology in mice

Enhancement of tumor metastasis and suppression of natural killer cell activity by beta-estradiol treatment.

Abstract 2116: Tumor-specific effects of estrogen drive a murine model of human estrogen receptor-positive breast cancer bone metastasis independent of bone microenvironment changes

Oestrogen deprivation induces chemokine production and immune cell recruitment in in vitro and in vivo models of oestrogen receptor-positive breast cancer

[Inhibitive Effects of Mifepristone on Growth of Breast Cancer: Experiment with Animal Model].

Effect of bilateral oophorectomy on mammary tumor formation in BRCA1 mutant mice.

Abstract 4968: Importance of tumor microenvironment in the preclinical estrogen receptor positive breast cancer- Primary tumor and bone metastasis models

Tumorigenesis and Neoplastic Progression Endometrial Tumorigenesis in Pten (cid:1) / (cid:2) Mice Is Independent of Coexistence of Estrogen and Estrogen Receptor (cid:1)

The Divergent Effects of Ovarian Steroid Hormones in the MCF-7 Model for Luminal A Breast Cancer: Mechanistic Leads for Therapy

A experimental study on endostatin treatment for breast cancer in mice

ANTICANCER ACTIVITY OF MIFERISTONE IN NUDE MICE WITH HUMAN ENDOMETRIAL CANCER

Effects of Estradiol and Tamoxifen on Proliferation of Human Breast Cancer Cells and Human Endometrial Cells.